With GLP-1 adoption rising from just 3% in 2021 to 23% in 2025, understanding why patients begin and continue these therapies has never been more important. Yet despite this rapid growth, nearly 75% of patients discontinue GLP-1 treatment within the first year.
To better understand this gap, we hosted a webinar exploring the factors that drive persistence with GLP-1 medications, drawing on insights from a December 2025 Thrivable research study of nearly 600 diabetes patients on GLP-1 therapy. The discussion brings together three unique perspectives—a patient, a healthcare provider, and a researcher to explore four key stages of the patient journey—awareness, prescribing, titration, and stabilization—highlighting where patients succeed, where they struggle, and what can be done to improve outcomes.
Guests:
Gary Scheiner, MS, CDCES, FADCES, Founder and Clinical Director at Integrated Diabetes Services
Maria Muccioli, Research Director at Thrivable
Liz B., Lives with Type 1 Diabetes, Mounjaro user
Host:
Sara Epstein, Product Director at Thrivable
To gain access to this webinar, simply complete the form below.
%20cropped.png)
